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APH   acetylphenylhydrazine 
Br    bilirubin reductase 
DTNB   5,5’-dithio-bis-2-nitrobenzoic acid 
FEV1   forced expiratory volume in 1 second 
GINA   Global Initiative for Asthma 
Gr    glutathione reductase 
GSH-Px/Gpx glutathione-peroxidase 
GSH   reduced glutathione 
GSSG   oxidized glutathione 
G6PD   glucose-6-phosphate dehydrogenase 
Hb    haemoglobin 
HMP   hexose monophosphate 
H2O2   hydrogen peroxide 
Ho    haemoxigenase 
metHb   methaemoglobin 
Mg    magnesium 
NADP   nicotinamide adenine dinucleotide phosphate 
NADPH  reduced nicotinamide adenine dinucleotide phosphate 
NEM   N-ethylmaleimide 
O2˙−   superoxide 
˙OH   hydroxyl radical 
oxyHb   oxyhaemoglobin 
RBC   red blood cell 
ROS   reactive oxygen species 











Bronchial asthma is characterized by variable and reversible airflow obstruction and 
by bronchial hyperresponsiveness in response to variety of apparently unrelated 
stimuli. Several inflammatory cells are found in asthmatic airways, including mast 
cells, macrophages, eosinophils, basophils, neutrophils, lymphocytes and platelets. 
These cells release a variety of mediators which interact in a complex manner to 
produce the pathophysiological features of asthma. 
Bronchial asthma is associated with uncompensated oxidative stress, which 
accompanies chronic airway inflammation and cell membrane and receptor damage. 
Several of the inflammatory cells such as mast cells, macrophages, eosinophils, 
neutrophils release reactive oxygen species (ROS) after activation by a variety of 
stimuli. They generate superoxide (O2˙−) which is rapidly converted to hydrogen 
peroxide (H2O2) by superoxide dysmutase (SOD). The hydroxyl radical (˙OH) is 
formed nonenzymatically in the presence of Fe2+ as a secondary reaction. In 
neutrophils myeloperoxidase also results in the formation hydrochlorous acid (HOCl) 
from H2O2 in the presence of chloride ions. HOCl is a potent oxidant. Several stimuli 
may release O2˙− from eosinophils, including opsonized zymosan, complement 
fragments, IgG and IgE. In the presence of halide ions, the enzyme eosinophil 
peroxidase and H2O2 form a potent cytoxic system against a variety of cells. Alveolar 
macrophages also generate oxygen metabolites by several stimuli, including IgE. 
Oxygen metabolites which are generated by inflammatory cells may stimulate nearby 
cells to release oxygen metabolites in a self-perpetuating cascade. Additionally, the 
airway epithelial cells themselves produce ROS, which may also stimulate 
inflammatory cells to release reactive oxygen metabolites. 
Oxidative stress develops when the levels of antioxidants are lowered and when 
production of free radicals exceeds the capacity of the cell to dispose of them. RBCs 
are particularly exposed to ROS as they lack the ability to synthesise new proteins 
and lipids. There are several antioxidant defence mechanisms which protect against 
ROS including the enzymes, SOD, catalase, glutathione peroxidase (GSH-Px). The 
main mechanism for generating reducing capacity in the erythrocytes is the pentose 
phosphate pathway. In this shunt off the main glycolytic pathway, glucose-6-
phosphate is oxidized by nicotinamide adenine dinucleotide phosphate (NADP), in a 
reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD), resulting in the 
production of reduced nicotinamide adenine dinucleotide phosphate (NADPH). The 
activity of hexokinase catalysing the formation of glucose-6-phosphate is a Mg-
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dependent process. NADPH enters the glutathione-dependent pathway by reducing 
oxidized glutathione (GSSG) to reduced glutathione (GSH) in a reaction catalyzed by 
glutathione reductase. A decrease in erythrocytes NADP biosynthesis leads to a 
diminution in cellular ability to reduce GSSG to GSH causing in a diminished ability 
of cells to defend against oxidant stress.  
In human and animal models, Mg deficiency leads to severe biochemical dysfunction 
and induces a variety of pathologies as a consequence of possible oxidative damage 
caused by free radicals. One mechanism by which Mg deprivation may increase 
cellular vulnerability to oxidation is by depleting reduced glutathione. In an 
oxidative environment there is an increased GSH consumption. The two enzymes that 
catalyze GSH synthesis, glutamate cysteine ligase (formerly called γ-glutamyl-
cysteine synthetase) and glutathione synthetase, are both Mg-dependent. 
The ratio of Mg retention to urinary excretion showed a significant inverse 
correlation with Mg concentration in erythrocytes. It has been shown that erythrocyte 
from Mg deficient hamster displayed an enhanced susceptibility to oxidative stress.  
 
AIMS 
First aim was to establish whether a Mg deficiency is indicated by a decreased 
urinary excretion and to determine whether 12-week oral Mg supplementation affects 
the Mg status and bronchodilator use in children with stable bronchial asthma in a 
randomized, double-blind, placebo-controlled study. 
Second aim was to investigate the effect of long-lasting oral Mg supplementation on 
the RBC redox system in stable, persistently moderately asthmatic children in a 
randomized, double-blind, placebo-controlled study. 
 
MATERIALS AND METHODS 
SUBJECTS AND STUDY DESIGN 
The first study was made of the effects of long-lasting oral Mg supplementation on 
the serum total and free Mg levels and the Mg excretion in the urine. 89 atopic 
asthmatic children (62 boys, 27 girls) aged 4-16 years were recruited. The patients 
exhibited persistent mild or moderate bronchial asthma on the GINA classification. 
The same protocol was used to study the effects of long-lasting oral Mg 
supplementation on the RBC redox system. Forty atopic asthmatic children (28 boys, 
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12 girls) aged 4-16 years were recruited. The recruited patients for this study 
exhibited persistent moderate bronchial asthma on the GINA classification.  
The diagnosis of bronchial asthma was based on the clinical, lung function, skin 
prick test, an elevated serum total IgE level, bronchial hyperreactivity and 
broncholysis test. Subjects were included only if their disease had been known for ≥6 
months, their diet was left unchanged, Mg supplementation had not been 
administered in the 4-week run-in period, short-term inhaled beta2-mimetics had 
been used as rescue medication only in cases of dyspnoea and wheeze, inhaled or 
systemic corticosteroids and other asthma medication had not been administered and 
they had had a serum Mg level ≤0.83 mmol/l. The investigation ran over three 4-
week treatment periods. During an initial 4-week period and the treatment period, the 
children ate their normal diet and short-term inhaled beta2-mimetics were 
administered if necessary. At each visit they received placebo or Mg capsules 
according to a randomized, double-blind protocol for the next 4-week period. The Mg 
intake was predetermined according to age within the groups. Children ≤7 years old 
received 200 mg, and children >7 years old received 290 mg Mg citrate daily, or 260 
mg glucose as a placebo, in capsule form each evening. The number of 
bronchodilator doses and symptom scores each day were recorded on a personal diary 
card. 
This study was approved by the Local Human Investigation Review Board of Albert 
Szent-Györgyi Medical University.  
DETERMINATION OF MAGNESIUM 
Mg forms a coloured complex with xylidyl blue in strongly basic solution, where 
calcium interference is eliminated by glycol ether diamine-N,N,N'N'-tetraacetic acid. 
The colour produced, measured biochromatically at 520/800 nm (Hitachi 917 
equipment), is proportional to the Mg concentration. Free Mg concentration in blood 
after haemolysis and from 24-h urine samples was determined with a blood gas 
analyser (NOVA 8 equipment), using a Mg-selective electrode. Most current blood 
analysers require a whole blood sample of <100 µl and measure pH, pCO2 and pO2 
simultaneously. 
DETERMINATIONS OF REDUCED AND OXIDIZED GLUTATHIONE  
The concentrations of GSSG+GSH and GSSG in whole blood haemolysates in the 
presence of cold 0.01 M sodium phosphate buffer containing 5 mM EDTA (pH=7.5) 
were measured by previously accepted highly sensitive and specific standard 
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methods. Depending on the concentrations of GSH (µmol/g Hb) and GSSG (nmol/g 
Hb) during the first 6 min, samples for both GSSG and GSH were measured 
spectrophotometrically at 412 nm in the presence of DTNB (0.6 µmol), glutathione 
reductase (10 µg), and NADPH (0.2 µmol). Samples for GSSG were measured after 
the alkylation of GSH with NEM and after the separation of GSSG and the NEM-
GSH complex by gel filtration with Sephadex G-10. The concentrations of GSH and 
GSSG were expressed with reference to Hb determined by the cyanmethaemoglobin 
method. 
REDUCED GLUTATHIONE STABILITY TEST 
Whole blood was incubated with 0.33 mmol APH and sufficient glucose at 37 °C for 
60 min. The residual GSH was expressed as a percentage of the original 
concentration. 
DETERMINATIONS OF OXIDIZED COMPONENTS OF HAEMOGLOBIN FROM HAEMOLYSATES 
Changes in oxidized components of Hb such as oxyhaemoglobin, methaemoglobin 
and hemichrome from haemolysates were examined before and after in vitro  
incubation with APH. Values were expressed as percentages. 
DETERMINATIONS OF PLASMA HAEMOGLOBIN, BILIRUBIN, OXYHAEMOGLOBIN, 
METHAEMOGLOBIN AND HEMICHROME  
Heparinized plasma samples were diluted 1:40 (v/v) with 5 mmol PBS (pH=7.4) and 
measured spectrophotometrically at different absorption wavelengths. 
  
RESULTS 
MAGNESIUM STATUS IN MILD AND MODERATE ASTHMATICS 
There was a significant increase in serum total Mg at the end of the study in both the 
Mg and the placebo treated patients in both the mild and the moderate asthmatics. 
The mean serum total Mg was significantly higher at the end in the magnesium group 
than in the placebo group in mild asthmatics, but not in moderate asthmatics.  
A statistically significant decrease was found in serum free Mg at the end of the Mg 
treatment period in mild asthmatics without clinical consequences. In moderate 
asthmatics no significant change has been observed. There was no change in serum 
free Mg at the end of the placebo treatment period either in mild or moderate 
asthmatic patients.  
The 24-hr Mg excretion was not significantly increased at the end of either the Mg or 
the placebo treatment period in mild asthmatics. There was a significant increase in 
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the mean 24-hr urine Mg excretion at the end of the Mg treatment and a significant 
decrease at the end of the placebo treatment in moderate asthmatics.  
CHANGES IN FEV1 IN MILD AND MODERATE ASTHMATICS 
There was a significantly increase FEV1 at the end of the study in both the Mg-
treated and the placebo-treated patients either in mild or moderate asthmatic patients. 
A significantly more frequent use of short-term inhaled beta2-mimetics as rescue 
medication produced the same increase in FEV1 in the later phase of the study in 
both groups of placebo-treated patients. 
BRONCHODILATOR USE 
The frequency of bronchodilator use decreased significantly at the end of the study in 
the Mg-treated patients than in the placebo-treated patients with moderate asthma. 
CHANGES IN SYMPTOM SCORES 
A significant decrease in daytime symptoms was experienced at 8 weeks in the Mg-
treated patients with moderate asthma. This decrease persisted at the end of the 
study. A significant change was also observed at 12 weeks in the placebo-treated 
patients with moderate asthma. No significant differences in any symptom scores 
were observed between the Mg-treated and the placebo-treated children with mild 
asthma. 
CHANGES IN REDOX SYSTEM 
Reduced and oxidized glutathione in the blood 
There was a significant increase in GSH concentration in the Mg-treated patients 
after the 12-week treatment period, but not in the placebo-treated group The GSSG 
concentration did not show any significant alterations during the 12-week treatment 
period in either the Mg-treated or the placebo-treated patients. 
Glutathione redox ratio 
A significant decrease in the molar ratio GSSG/GSH was observed in the placebo-
treated patients after 12 weeks, but not in the Mg-treated patients. A significant 
decrease in GSSG/GSH associated with an insignificant decrease in GSSG 





Reduced glutathione stability test 
The GSH stability test revealed that the residual capacity of the RBCs after an in 
vitro challenge with APH was significantly lower. The stability tests were 
approximately 42% before the treatment period and exhibited significant decrease at 
the end of the study in both the Mg-treated and the placebo-treated groups, as a sign 
of the increased sensitivity and the decreased antioxidant capacity of patients to 
resist an oxidative challenge. 
Oxidized haemoglobin derivatives in the plasma 
The plasma oxyHb concentration measured at 560 nm was not changed either in the 
Mg-treated or in the placebo-treated children after the treatment period as compared 
with the baseline values. However, the metHb, the hemichrome and the bilirubin 
values were significantly decreased to similar extents in both groups.  
Whole blood and plasma haemoglobin concentrations 
The plasma Hb levels were significantly decreased to different extents in both the 
Mg-treated and the placebo-treated groups. In parallel, we observed significant 
increases in the whole blood Hb concentrations in both groups.  
Whole blood oxyhaemoglobin, methaemoglobin and hemichrome concentrations 
Measurements of the whole blood oxyHb, metHb and hemichrome concentrations in 
the hemolysate were performed after the GSH determination. No significant 
differences before and after the treatment period were found in either group. 
However, the oxyHb concentrations displayed significant decreases after an in vitro  
oxidative challenge with APH in both groups. The metHb concentration was 
considerably higher in the Mg-treated patients after acute oxidative stress than in the 
placebo-treated patients. There was no significant alteration in the hemichrome 
concentrations before and after the treatment period in either group (except for the 
hemichrome level which displayed an increasing tendency in the placebo-treated 
patients). 
Linear regression between plasma haemoglobin concentration and plasma 
methaemoglobin and hemichrom levels 
Analysis of regression demonstrated positive correlations, with significantly 
decreased plasma metHb and hemichrome levels and a decreased plasma Hb 




1. Our study demonstrated that the total and free Mg level in the serum and 
urine in mildly or moderately asthmatic children on a normal diet were 
close to the lower levels of the normal range. 
2. The measurement of the total and/or free Mg levels in the serum alone is 
not sufficient for a characterization of the Mg status. 
3. Determination of the 24-hr urine Mg excretion is an important and simply 
way to assess a Mg deficit. 
4. Based on the Mg excretion in urine, a Mg deficiency could be detected in 
moderately asthmatic children, who administered only short-term inhaled 
beta2-mimetics if necessary. 
5. A significantly more frequent use of short-term inhaled beta2-mimetics as 
rescue medication produced the same increase in FEV1 in the later phase of 
the study in both groups of placebo-treated patients. 
6. The significant reduction in bronchodilator use in children with moderate 
asthma versus placebo group suggests the benefit of Mg supplementation. 
7. Improvement of the daytime clinical symptoms could be considered 
moderate during a 12-week Mg treatment period. 
8. A long-term Mg supplementation was able to elevate the GSH concentration 
indicating that other compensatory mechanisms serving the defence against 
oxidative agents were activated to maintain the normal GSH level in 
children with moderate asthma. 
9. The GSH capacity of the RBCs was about 42% in children with moderate 
asthma. 
10. More significantly reduced plasma Hb concentrations and in parallel a 
significantly decreased plasma metHb and hemichrome levels which are 
products of the oxidative haemolysis were observed suggesting the benefit 
of Mg supplementation in the Mg-treated patients. 
In general, nutritional Mg therapy for bronchial asthma palliates the coexistent 
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